Amid plans to transfer manufacturing for an investigational vaccine to a souped-up plant in Pennsylvania, GSK is parting ways ...

A global biopharmaceutical company headquartered in London announced the layoffs of 150 Massachusetts employees last week.

After calling Rockville, Maryland, home for more than eight years, GSK's vaccine and infectious disease R&D teams are planning a move northeast to Cambridge, Massachusetts, the company confirme ...

After making a splash in the U.K. earlier this year, GSK is laying out plans for its biggest U.S. manufacturing investment yet. GSK is investing up to $800 million to double the size and capacity ...

The funding, which brings GSK’s expenditure in US manufacturing capabilities close to $1.3bn, will establish a new vaccines drug substance facility and an R&D pilot plant.

Vaccine manufacturer GSK plans to invest $800 million in its Lancaster County facility, creating 200 new jobs and expanding its manufacturing and R&D capabilities.

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...